

Cancer Conference Update



Audio reviews of key presentations and posters from important scientific meetings

Discussion of 65 Presentations and Posters from the 2009 Annual Oncology Meeting in Orlando, Florida

EDITOR

Neil Love, MD

INTERVIEWS

Charles D Blanke, MD

Everett E Vokes, MD

Rafael Fonseca, MD

Harold J Burstein, MD, PhD

Deborah K Armstrong, MD

William K Oh, MD

Myron S Czuczman, MD



From the publishers of:

Breast Cancer®
UPDATE

Colorectal Cancer™
UPDATE

Lung Cancer™
UPDATE

Hematologic
Oncology™
UPDATE

Prostate Cancer™
UPDATE

Renal Cell Cancer™
UPDATE



Subscribe to Podcasts or download MP3s of this program at ResearchToPractice.com/CACU209

Cancer Conference Update

A Continuing Medical Education Audio Series

OVERVIEW OF ACTIVITY

Oncology is one of the most rapidly evolving fields in medicine. Results presented at major cancer conferences from a myriad of ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, medical oncologists must be well informed of these advances.

To bridge the gap between research and clinical practice, this issue of *Cancer Conference Update* features one-on-one discussions with Drs Blanke, Vokes, Fonseca, Burstein, Armstrong, Oh and Czuczman about the integration of data presented at the 2009 American Society of Clinical Oncology Annual Meeting in Orlando, Florida into management strategies for patients with a variety of cancer types. Thus, this CME activity is designed to assist medical oncologists with the formulation of up-to-date treatment approaches.

LEARNING OBJECTIVES

- Employ an individualized patient assessment to tailor the use of cytotoxic, biologic and/or small-molecule targeted therapy for non-small cell lung cancer.
- Recognize the emerging contribution of induction chemotherapy and biologic agents to standard chemoradiation therapy approaches for head & neck cancer.
- Communicate the benefits and risks of anti-angiogenic therapy in combination with chemotherapeutics to appropriate patients with advanced breast cancer.
- Counsel patients with ovarian cancer about current approaches to recurrence surveillance and the benefits/risks of standard and novel systemic treatment strategies.
- Develop a therapeutic algorithm for the collective use of tyrosine kinase inhibitors, anti-angiogenic agents and/or cytokines in the management of metastatic renal cell carcinoma.
- Assess the practical implications of emerging research using cytotoxic, biologic and novel androgen-targeted agents for the treatment of castration-refractory, metastatic prostate cancer.
- Demonstrate knowledge of research advances using novel schedules, regimens or agents for the systemic management of hematologic cancers.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 4 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at CME.ResearchToPractice.com.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals Inc and Sanofi-Aventis.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — **Dr Burstein** had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Blanke** — Advisory Committee: Genentech BioOncology, Novartis Pharmaceuticals Corporation, Oncothyreon, Roche Laboratories Inc. **Dr Vokes** — Advisory Committee: Bayer Pharmaceuticals Corporation; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, ImClone Systems Incorporated, OSI Oncology, Sanofi-Aventis. **Dr Fonseca** — Advisory Committee: Bristol-Myers Squibb Company; Consulting Agreements: Amgen Inc, Celgene Corporation, Genzyme Corporation. **Dr Armstrong** — Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology. **Dr Oh** — Advisory Committee: Genentech BioOncology, GPC Biotech, Sanofi-Aventis, Wyeth; Speakers Bureau: Sanofi-Aventis. **Dr Czuczman** — Advisory Committee: Amgen Inc, Biogen Idec, Celgene Corporation, Cephalon Inc, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation; Lectures: Biogen Idec, Genentech BioOncology.

EDITOR — **Neil Love**: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, Eli Lilly and Company, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

If you would like to discontinue your complimentary subscription to *Cancer Conference Update*, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

AUDIO PROGRAM GUIDE

PAPERS DISCUSSED BY CHARLES D BLANKE, MD (GASTROINTESTINAL CANCERS)

1 Abstract LBA4509 — ToGA: A Phase III trial of chemotherapy with or without trastuzumab as first-line therapy for HER2-positive advanced gastric cancer

2 Abstract LBA4 — NSABP-C-08: A Phase III trial of mFOLFOX6 with or without bevacizumab for Stage II/III colon cancer

3 Abstract 4000 — Quantitative multigene RT-PCR assay to predict the risk of recurrence for Stage II colon cancer: The QUASAR validation study

4 Abstract CRA4030: Combination chemotherapy without surgery as initial treatment for synchronous, Stage IV colorectal cancer

5 Abstract 4025: Impact of calcium/magnesium versus placebo on acute and chronic neurotoxicity associated with adjuvant FOLFOX for patients with colorectal cancer

6 Abstracts LBA4007, CRA4008 — ACCORD, STAR-01: Phase III randomized trials of neoadjuvant oxaliplatin as part of chemoradiation therapy for locally advanced rectal cancer

7 Abstract 4525: A Phase I/II trial with SPARC correlatives of nanoparticle albumin-bound (*nab*) paclitaxel/gemcitabine for previously untreated metastatic pancreatic cancer

8 Abstract 4532 — AViTA: A Phase III trial of erlotinib/gemcitabine with or without bevacizumab for previously untreated metastatic pancreatic cancer

9 Abstracts 10508, 10549 — French Sarcoma Group BFR-14: A Phase III trial evaluating maintenance imatinib for advanced gastrointestinal stromal tumor

10 Abstract 4503 — ABC-02: A Phase III trial of gemcitabine with or without cisplatin for previously untreated advanced biliary tract cancer

11 Abstract 4522: A Phase II trial of bevacizumab/erlotinib for advanced hepatocellular carcinoma

PAPERS DISCUSSED BY EVERETT E VOKES, MD (HEAD & NECK AND LUNG CANCERS)

1 Abstract 6009: Chemoradiation therapy (CRT) alone versus induction chemotherapy — cisplatin/5-FU (CF) versus docetaxel/cisplatin/5-FU (TPF) — followed by CRT as first-line therapy for unresectable locally advanced head & neck cancer (HNC)

2 Abstract 6012: A Phase II trial of bevacizumab and erlotinib with radiation therapy and chemotherapy as first-line therapy for locally advanced squamous cell HNC

3 Abstract 7501 — Updated survival analysis of JBR.10: Adjuvant cisplatin/vinorelbine versus observation for Stage IB/II non-small cell lung cancer (NSCLC)

4 Abstract 7523: Impact on disease-free survival of adjuvant erlotinib or gefitinib for patients with resected lung adenocarcinomas that harbor EGFR mutations

5 Abstract 8006 — IPASS: Biomarker analysis from a Phase III trial of gefitinib versus carboplatin/paclitaxel for clinically selected patients with advanced NSCLC

6 Abstract 7528: Incorporating bevacizumab and erlotinib with induction chemotherapy and concurrent chemoradiation therapy for Stage III NSCLC

7 Abstract CRA8000: Best supportive care with maintenance pemetrexed versus placebo for advanced NSCLC that has not progressed on four cycles of platinum-based chemotherapy

8 Abstracts 8001, LBA8002 — SATURN, ATLAS: Trials evaluating maintenance therapy with erlotinib or erlotinib/bevacizumab for advanced NSCLC

PAPERS DISCUSSED BY RAFAEL FONSECA, MD (MULTIPLE MYELOMA, AMYLOIDOSIS AND WALDENSTRÖM MACROGLOBULINEMIA)

1 Abstract 8516: Induction therapy with bortezomib, intravenous cyclophosphamide and dexamethasone (VelCD) for newly diagnosed multiple myeloma (MM)

2 Abstract 8517: A Phase I/II trial of lenalidomide/bortezomib/pegylated liposomal doxorubicin (PLD)/dexamethasone for newly diagnosed MM

3 Abstract 8518: A Phase II trial of PLD/low-dose dexamethasone/lenalidomide for newly diagnosed MM

4 Abstract 8515: A Phase III trial of bortezomib/melphalan/prednisone/thalidomide (VMPT) versus VMP for elderly patients with newly diagnosed MM

5 Abstract 8596: Autologous stem cell transplant following induction therapy with bortezomib/lenalidomide/dexamethasone or bortezomib/thalidomide/dexamethasone for newly diagnosed MM

6 Abstract 7096: Effect of mobilization chemotherapy (cyclophosphamide/etoposide) on stem cell collection after induction lenalidomide/dexamethasone for MM

7 Abstract 8536: A Phase II trial of lenalidomide/bortezomib/dexamethasone (RVD) for relapsed/refractory MM

8 Abstract 8540: A Phase II trial of risk-adapted melphalan and stem cell transplant followed by bortezomib/dexamethasone for light-chain amyloidosis

9 Abstract 8535: A Phase II trial of bortezomib/rituximab for relapsed/refractory Waldenström macroglobulinemia

PAPERS DISCUSSED BY HAROLD J BURSTEIN, MD, PHD (BREAST CANCER)

1 Abstracts CRA508, CRA509: Administration of CYP2D6 inhibitors and the efficacy of adjuvant tamoxifen

2 Abstract CRA501: Olaparib, an oral PARP inhibitor, for BRCA-deficient, chemotherapy-refractory metastatic breast cancer (mBC)

3 Abstract 3: A Phase II randomized trial of gemcitabine/carboplatin with or without BSI-210 — a PARP1 inhibitor — for triple-negative mBC

4 Abstract 1017: A Phase II trial of trastuzumab-DM1 (T-DM1) for HER2-positive mBC previously treated with anti-HER2 therapy

5 Abstract 1022: A trial evaluating pertuzumab for HER2-positive mBC that has progressed on trastuzumab

6 Abstract 1005 — RIBBON 1: Chemotherapy with or without bevacizumab as first-line therapy for HER2-negative, locally recurrent or mBC

7 Abstract 1006: A Phase II randomized trial evaluating three schedules of *nab* paclitaxel in combination with bevacizumab as first-line therapy for HER2-negative mBC

8 Abstract 1018 — Biomarker analysis of EGF30008: Progression-free survival with the addition of lapatinib to letrozole for HER2-negative, ER-low mBC

9 Abstract 1050: A Phase II trial of fulvestrant 500 milligrams as first-line hormonal therapy for postmenopausal women with ER-positive mBC

PAPERS DISCUSSED BY DEBORAH K ARMSTRONG, MD (OVARIAN CANCER)

- 1 Abstract 1 — MRC-OVO5/EORTC-55955: Early treatment based on CA125 versus delayed treatment based on clinical indicators for relapsed ovarian cancer
- 2 Clinical activity and side effects of bevacizumab for ovarian cancer
- 3 Abstracts 5539, 5540: Safety and feasibility of combining intravenous bevacizumab with intraperitoneal therapy for ovarian, primary peritoneal or fallopian tube cancer
- 4 Abstract LBA5509 — CALYPSO: Carboplatin/PLD versus carboplatin/paclitaxel for relapsed platinum-sensitive ovarian cancer
- 5 Abstract 5500: A Phase II trial of olaparib for BRCA-deficient advanced ovarian cancer
- 6 Abstract 5531 — GOG-0229E: A Phase II trial of bevacizumab for recurrent or persistent endometrial cancer

PAPERS DISCUSSED BY WILLIAM K OH, MD (RENAL CELL AND PROSTATE CANCER)

- 1 Abstracts LBA5019, 5020 — CALGB-90206, AVOREN: Phase III trials of interferon alpha with or without bevacizumab for newly diagnosed metastatic renal cell carcinoma (mRCC)
- 2 Abstract 5004: A Phase II trial of neoadjuvant bevacizumab/erlotinib or bevacizumab alone for previously untreated mRCC
- 3 Abstracts 5021, 5110: A Phase III randomized trial of pazopanib versus placebo with open-label extension for treatment-naïve or cytokine-pretreated mRCC
- 4 Abstract 5037: A Phase I trial of everolimus/sunitinib for mRCC
- 5 Abstract 5018 — HOG-GU-0475: Cisplatin/gemcitabine and bevacizumab as first-line therapy for metastatic urothelial carcinoma
- 6 Abstract 5060: A Phase II trial of neoadjuvant docetaxel/bevacizumab for high-risk, localized prostate cancer (PC)
- 7 Abstract 5047: A Phase II trial of abiraterone for docetaxel-pretreated, castration-resistant PC
- 8 Abstract 5057: A Phase I/II trial of docetaxel/samarium for castrate, metastatic PC

PAPERS DISCUSSED BY MYRON S CZUCZMAN, MD (NON-HODGKIN LYMPHOMAS/CHRONIC LYMPHOCYTIC LEUKEMIA)

- 1 Abstracts 7043, 7044: Activity of ofatumumab for fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL) with an analysis according to prior rituximab exposure
- 2 Mechanism of action of ofatumumab
- 3 Tolerability of ofatumumab
- 4 Evolving clinical research for ofatumumab
- 5 Abstract 2: A Phase III trial of idiotype vaccine therapy (BiovaxID) versus placebo for follicular lymphoma in first complete remission
- 6 Abstract 8512 — SAKK-35/98: A Phase III randomized trial of single-agent rituximab followed by observation or consolidation with rituximab for follicular lymphoma
- 7 Abstract 8548: Lenalidomide/rituximab as first-line therapy for indolent NHL
- 8 Abstract 8506: R-CHOP14 versus R-CHOP21 for newly diagnosed diffuse large B-cell lymphoma (DLBCL)
- 9 Abstract 8569 — NHL-003: Lenalidomide for relapsed/refractory mantle-cell lymphoma
- 10 Abstract 8524: A Phase II trial of lenalidomide for relapsed/refractory T-cell lymphoma

QUESTIONS (PLEASE CIRCLE ANSWER):

- Both CALGB-90206 and AVOREN demonstrated that the addition of bevacizumab to interferon alpha as first-line therapy for metastatic renal cell carcinoma significantly improved _____.**
 - Progression-free survival
 - Overall survival
 - Both a and b
 - None of the above
- CALGB is conducting a Phase III randomized trial evaluating the addition of bevacizumab to docetaxel for castration-resistant metastatic prostate cancer.**
 - True
 - False
- In ToGA — a Phase III randomized trial for HER2-positive advanced gastric cancer — the addition of trastuzumab to standard chemotherapy significantly improved _____.**
 - Overall survival
 - Progression-free survival
 - Response rates
 - All of the above
- In NSABP-C-08, the addition of one year of bevacizumab to mFOLFOX6 significantly improved the three-year disease-free survival rate for patients with Stage II/III colon cancer.**
 - True
 - False
- In a Phase I/II trial of *nab* paclitaxel/ gemcitabine for previously untreated metastatic pancreatic cancer, patients with SPARC-positive disease were more likely to respond to therapy.**
 - True
 - False
- In a randomized trial comparing early treatment based on CA125 to delayed treatment based on clinical indicators for relapsed ovarian cancer, no difference in overall survival was found.**
 - True
 - False
- The CALYPSO trial demonstrated that carboplatin in combination with _____ had greater efficacy and was more tolerable than carboplatin in combination with paclitaxel for relapsed platinum-sensitive ovarian cancer.**
 - Docetaxel
 - Pegylated liposomal doxorubicin
 - Bevacizumab
 - Both a and c
 - None of the above
- Olaparib belongs to which class of agents?**
 - Tyrosine kinase inhibitors
 - PARP inhibitors
 - Angiogenesis inhibitors
 - None of the above
- Which of the following chemotherapy regimens was evaluated in JBR.10 as adjuvant therapy for Stage IB/II NSCLC?**
 - Cisplatin/paclitaxel
 - Cisplatin/vinorelbine
 - Cisplatin/gemcitabine
 - All of the above
 - None of the above

QUESTIONS (PLEASE CIRCLE ANSWER):

10. In a Phase III randomized trial for patients with advanced NSCLC that had not progressed on four cycles of a platinum-based chemotherapy, patients who received maintenance pemetrexed had better outcomes than those who received _____.
- Placebo
 - Bevacizumab
 - Erlotinib
 - Cetuximab
11. In a Phase III randomized trial comparing VMPT to VMP for elderly patients with newly diagnosed multiple myeloma, the rate of neurotoxicity was reduced when bortezomib was administered _____.
- Weekly
 - Twice weekly
 - Monthly
 - None of the above
12. Which of the following regimens has been evaluated as induction therapy for newly diagnosed multiple myeloma?
- Bortezomib/intravenous cyclophosphamide/dexamethasone
 - Lenalidomide/bortezomib/pegylated liposomal doxorubicin/dexamethasone
 - Pegylated liposomal doxorubicin/low-dose dexamethasone/lenalidomide
 - All of the above
 - None of the above
13. Which of the following agents has activity in patients with HER2-positive metastatic breast cancer that has progressed on trastuzumab?
- T-DM1
 - Pertuzumab
 - Bortezomib
 - Both a and b
 - All of the above
14. Which of the following trials evaluated the efficacy of bevacizumab in combination with chemotherapy as first-line therapy for metastatic breast cancer?
- ECOG-E2100
 - AVADO
 - RIBBON 1
 - All of the above
 - None of the above
15. In patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory CLL, ofatumumab had similar activity, irrespective of prior exposure to rituximab.
- True
 - False
16. In a Phase III randomized trial for patients with newly diagnosed diffuse large B-cell lymphoma, R-CHOP14 was _____ to R-CHOP21 in terms of overall survival.
- Superior
 - Inferior
 - Comparable

EDUCATIONAL ASSESSMENT AND CREDIT FORM

Cancer Conference Update — Issue 2, 2009

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART ONE — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Overall survival improvement when trastuzumab is combined with chemotherapy for HER2-positive metastatic gastric cancer	4 3 2 1	4 3 2 1
Treatment with <i>nab</i> paclitaxel in metastatic pancreatic cancer and the correlation of clinical response with SPARC and serum CA19-9 levels	4 3 2 1	4 3 2 1
Improvement in time to progression with induction chemotherapy prior to chemoradiation therapy for locally advanced head & neck cancer	4 3 2 1	4 3 2 1
Maintenance therapy with biologic agents in metastatic NSCLC	4 3 2 1	4 3 2 1
Induction regimens for newly diagnosed MM that include bortezomib and/or lenalidomide	4 3 2 1	4 3 2 1
Trials combining intravenous bevacizumab with intraperitoneal chemotherapy for ovarian cancer	4 3 2 1	4 3 2 1
Phase III trial data with pazopanib in advanced renal cell carcinoma	4 3 2 1	4 3 2 1
Clinical activity of ofatumumab in fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory CLL	4 3 2 1	4 3 2 1

Was the activity evidence based, fair, balanced and free from commercial bias?

Yes No

If no, please explain:

Will this activity help you improve patient care?

Yes No Not applicable

If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Employ an individualized patient assessment to tailor the use of cytotoxic, biologic and/or small-molecule targeted therapy for non-small cell lung cancer. . . . 4 3 2 1 N/M N/A
- Recognize the emerging contribution of induction chemotherapy and biologic agents to standard chemoradiation therapy approaches for head & neck cancer. 4 3 2 1 N/M N/A
- Communicate the benefits and risks of anti-angiogenic therapy in combination with chemotherapeutics to appropriate patients with advanced breast cancer. . . . 4 3 2 1 N/M N/A
- Counsel patients with ovarian cancer about current approaches to recurrence surveillance and the benefits/risks of standard and novel systemic treatment strategies. 4 3 2 1 N/M N/A
- Develop a therapeutic algorithm for the collective use of tyrosine kinase inhibitors, anti-angiogenic agents and/or cytokines in the management of metastatic renal cell carcinoma. 4 3 2 1 N/M N/A
- Assess the practical implications of emerging research using cytotoxic, biologic and novel androgen-targeted agents for the treatment of castration-refractory, metastatic prostate cancer. 4 3 2 1 N/M N/A
- Demonstrate knowledge of research advances using novel schedules, regimens or agents for the systemic management of hematologic cancers. 4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

Did the activity meet your educational needs and expectations?

Yes No

If no, please explain:

What other practice changes will you make or consider making as a result of this activity?

What additional information or training do you need on the activity topics or other oncology-related topics?

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

Yes, I am willing to participate in a follow-up survey.
 No, I am not willing to participate in a follow-up survey.

PART TWO — Please tell us about the faculty and editor for this educational activity

	4 = Excellent	3 = Good	2 = Adequate	1 = Suboptimal		4	3	2	1
Faculty	Knowledge of subject matter				Effectiveness as an educator				
Charles D Blanke, MD	4	3	2	1	4	3	2	1	
Everett E Vokes, MD	4	3	2	1	4	3	2	1	
Rafael Fonseca, MD	4	3	2	1	4	3	2	1	
Harold J Burstein, MD, PhD	4	3	2	1	4	3	2	1	
Deborah K Armstrong, MD	4	3	2	1	4	3	2	1	
William K Oh, MD	4	3	2	1	4	3	2	1	
Myron S Czuczman, MD	4	3	2	1	4	3	2	1	
Editor	Knowledge of subject matter				Effectiveness as an educator				
Neil Love, MD	4	3	2	1	4	3	2	1	

Please recommend additional faculty for future activities:

Other comments about the faculty and editor for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: Specialty:

Professional Designation:

MD DO PharmD NP RN PA Other

Medical License/ME Number: Last 4 Digits of SSN (required):

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

Research To Practice designates this educational activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: Date:

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at CME.ResearchToPractice.com.

Cancer Conference Update

Editor	Neil Love, MD
Managing Editor	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Senior Director, Medical Affairs	Aviva Asnis-Alibozek, PA-C, MPAS
Writers	Lillian Sklaver Poltorack, PharmD Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng Erin Wall Clayton Campbell
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Graphic Designers	Jessica Benitez Jason Cunniss Tamara Dabney Deepti Nath
Senior Production Editor	Alexis Oneca
Traffic Manager	Tere Sosa
Copy Editors	Margo Harris David Hill Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager	Tracy Potter
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Faculty Relations Manager	Melissa Vives
CME Director/CPD Director	Isabelle Vacher
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com
For CME/CNE Information	Email: CE@ResearchToPractice.com

Copyright © 2009 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Cancer Conference **Update**

Copyright © 2009 Research To Practice.

This program is supported by educational grants from
Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Celgene Corporation,
Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals Inc and Sanofi-Aventis.

Research
To Practice®

Sponsored by Research To Practice.

Last review date: August 2009

Release date: August 2009

Expiration date: August 2010

Estimated time to complete: 4 hours